Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Collection of Samples USOPTIVAL Study
NCT04792684 · View on ClinicalTrials.gov ↗
Study Summary
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Study Locations (16)
California
- Precision Recearch Institute — Chula Vista
- Precision Research Institute — San Diego
- Medical Associates Research Group — San Diego
- Clinical Research of California — Walnut Creek
Pennsylvania
- University of Pennsylvania — Philadelphia
- Fox Chase Cancer Center — Philadelphia
- Frontier Clinical Research — Uniontown
Florida
- Center for Gastrointestinal Disorders — Hollywood
- Lakeland Regional Cancer Center — Lakeland
Illinois
- Springfield Clinic — Springfield
Louisiana
- Ochsner Clinic — New Orleans
Massachusetts
- Dana Farber Cancer Institute — Boston
New York
- Mid Hudson Medical Research — New Windsor
Tennessee
- Clinical Trials Network — Union City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,300 participants |
| Start Date | 2020-12-30 |
| Est. Completion | 2025-12-30 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04792684
The ClinicalTrials.gov registry entry for NCT04792684 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Universal Diagnostics, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Colorectal Cancer (CRC) appearing as the primary indexed condition, and to 1 intervention — of which Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04792684 reports 16 study locations spanning 10 distinct geographic areas — top geographies include California, Pennsylvania, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04792684 about?
NCT04792684 is a clinical study titled "Collection of Samples USOPTIVAL Study". A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
What is the current status of trial NCT04792684?
This trial is currently recruiting. The enrollment target is 1,300 participants. The study started on 2020-12-30. Estimated completion is 2025-12-30.
What conditions does trial NCT04792684 study?
This clinical trial studies the following conditions: Colorectal Cancer (CRC), Advanced Adenomas (AA). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04792684?
The interventions under investigation include: Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04792684?
This trial is sponsored by Universal Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04792684 being conducted?
This trial has 16 study locations across California, Florida, Illinois, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.